The Carlos III Health Institute (ISCIII) has recently published the recipients of grants for the promotion of biomedical and health research in Spain. The investment was made as part of the Strategic Action in Health 2024 (AES 2024) call, which is the main source of funding for health research in Spain.

A total of 50 projects of the Vall d'Hebron Accredited Institute, as an ISCIII-accredited institute, will receive funding as part of the call for R&D&I projects in health. In total, 8.3 million euros will be allocated to different areas of health and pathologies, such as rheumatological and neurodegenerative diseases, multiple sclerosis and cancer. These include projects focusing on paediatric and adolescent research, carried out by groups belonging to the Vall d'Hebron Research Institute's Paediatric Research Hub.

The institution tops the national table in terms of the number of projects awarded and the amount of funding received.
Funding has also been granted for two other projects in the calls for Technological Development in Health and Independent Clinical Research in cancer and renal transplantation, respectively.

These figures reflect the Vall d'Hebron Campus' leadership role in the field of research and consolidate its position as a benchmark in innovation and achieving health improvement through science.
Here is a list of the groups and researchers who are heading the awarded projects:

Call for R&D&I in Health Projects

• Laura Abraira and Estevo Santamarina of the VHIR Epileptic State and Acute Crises Research Group
• Silvia Alemany of the VHIR Psychiatry, Mental Health and Addictions Group
• Silvia Amoretti of the VHIR Psychiatry, Mental Health and Addictions Group
• Miriam Barrecheguren and Marc Miravitlles of the VHIR Pulmonology Group
• Erika Bonacina of the VHIR Maternal and Fetal Medicine Group
• Jordi Bové and Oriol de Fàbregues-Boixar of the VHIR Neurodegenerative Diseases Group
• Maria Clemente and Nuria Camats of the VHIR Growth and Development Group
• Alvaro Cobo of the VHIR Clinical Neuroimmunology Group
• Manuel Comabella of the VHIR Clinical Neuroimmunology Group
• Josefina Cortés of the VHIR Rheumatology Group
• Carmen Espejo of the VHIR Clinical Neuroimmunology Group
• Diana Fernandes and Simo Schwartz of the VHIR Clinical Biochemistry, Drug Delivery and Therapy Group
• Elena Fonseca of the VHIR Epileptic State and Acute Crises Research Group
• Antonio Gil and Melissa Bradbury of the VHIR Biomedical Research in Gynaecology Group
• Juan José González of the VHIR Microbiology Group
• Sleiman Haddad of the VHIR Spine Research Unit
• José Raúl Herance of the Molecular Medical Imaging Group and Olga Simó of the Diabetes and Metabolism Group at VHIR
• Concepció Jacobs and Juan López of the VHIR Clinical Biochemistry, Drug Delivery and Therapy Group
• Joan Joseph Munné and Vivian Salazar of the VHIR Microbiology Group
• Miquel Eduard Kraft Carré of the VHIR General Surgery Group
• Ariadna Laguna of the VHIR Neurodegenerative Diseases Group
• Matilde Lleonart of the VHIR Head and Neck Cancer: Biomedical Research on Tumour Stem Cells Group
• María del Mar Mañú Pereira of the VHIR Childhood Cancer and Haematological Diseases Group
• Ramon Martí of the VHIR Neuromuscular and Mitochondrial Pathology Group
• Cristina Martínez of the VHIR Renal Physiopathology Group
• Marta Martínez and Jorge Hernández of the VHIR Neurodegenerative Diseases Group
• Jaume Mestre and Maria Roser Solans of the VHIR Systemic Diseases Group
• Andrés Miguez of the VHIR Clinical Neuroimmunology Group
• Enric Miret and Enrique Trilla of the VHIR Biomedical Research in Urology Group
• Francesc Miró and Jaume Alijotas of the VHIR Systemic Diseases Group
• Lucas Moreno of the VHIR Children's Cancer and Haematological Diseases Group
• Xavier Muñoz of the VHIR Pulmonology Group
• Miriam de Nadal of the VHIR Neurotraumatology and Neurosurgery Research Unit (UNINN)
• Jorge Pagola of the VHIR Stroke Research Group
• Belen Perez and Anna Marcé of the VHIR Therapies and Innovation in Neuropaediatrics and Other Rare Paediatric Diseases Group
• Josep Roma of the VHIR Childhood Cancer and Haematological Diseases Group
• Sandra Rovira and Antonio Moreno of the VHIR Growth and Development Group
• Maria José Soler and Sheila Bermejo of the VHIR Nephrology and Renal Transplant Group
• Carmen Tur of the VHIR Clinical Neuroimmunology Group
• Francesc Bosch of the VHIO Experimental Haematology Group
• Irene Braña of the VHIO Head and Neck Cancer Group
• Jaume Capdevila of the VHIO Gastrointestinal and Endocrine Tumours Group
• María Elena Elez of the VHIO Colorectal Cancer Group
• Teresa Macarulla of the VHIO Upper Gastrointestinal and Endocrine Tumours Group
• Javier Maldonado of the VHIO Radiation Oncology Group
• Paolo Giovanni Nuciforo of the VHIO Molecular Oncology Group
• Raquel Pérez of the VHIO Radiomics Group
• Isabel Puig of the VHIO Stem Cells and Cancer Group
• Cristina Saura of the VHIO Breast Cancer Group
• Ana Vivancos of the VHIO Cancer Genomics Group

Health Technology Development

• Marcos Malumbres of the VHIO Cell Cycle and Cancer Group

Independent Clinical Research

• Oriol Bestard of the VHIR Nephrology and Renal Transplant Group